Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 703

1.

Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.

Arnst KE, Wang Y, Lei ZN, Hwang DJ, Kumar G, Ma D, Parke DN, Chen Q, Yang J, White SW, Seagroves TN, Chen ZS, Miller DD, Li W.

Mol Pharmacol. 2019 Jul;96(1):73-89. doi: 10.1124/mol.118.114801. Epub 2019 May 1.

PMID:
31043459
2.

Addressing the Diversity-Validity Dilemma Using Situational Judgment Tests.

Juster FR, Baum RC, Zou C, Risucci D, Ly A, Reiter H, Miller DD, Dore KL.

Acad Med. 2019 Apr 23. doi: 10.1097/ACM.0000000000002769. [Epub ahead of print]

PMID:
31033603
3.

Fisetin and 5-fluorouracil: Effective combination for PIK3CA-mutant colorectal cancer.

Khan N, Jajeh F, Eberhardt EL, Miller DD, Albrecht DM, Van Doorn R, Hruby MD, Maresh ME, Clipson L, Mukhtar H, Halberg RB.

Int J Cancer. 2019 Apr 24. doi: 10.1002/ijc.32367. [Epub ahead of print]

PMID:
31018249
4.

Polymeric Micellar Delivery of Novel Microtubule Destabilizer and Hedgehog Signaling Inhibitor for Treating Chemoresistant Prostate Cancer.

Yang R, Chen H, Guo D, Dong Y, Miller DD, Li W, Mahato RI.

J Pharmacol Exp Ther. 2019 Apr 17. pii: jpet.119.256628. doi: 10.1124/jpet.119.256628. [Epub ahead of print]

5.

Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10.

Noe MH, Rosenbach M, Hubbard RA, Mostaghimi A, Cardones AR, Chen JK, Cotliar J, Davis MDP, Dominguez A, Fox LP, Hughey LC, Kaffenberger BH, Kroshinsky D, Kwong BY, Miller DD, Musiek A, Ortega-Loayza AG, Sharon VR, Shinkai K, Summers EM, Wanat KA, Wetter DA, Worswick S, Margolis DJ, Gelfand JM, Micheletti RG.

JAMA Dermatol. 2019 Mar 6. doi: 10.1001/jamadermatol.2018.5605. [Epub ahead of print]

PMID:
30840032
6.

Recurrent corneal erosion: a comprehensive review.

Miller DD, Hasan SA, Simmons NL, Stewart MW.

Clin Ophthalmol. 2019 Feb 11;13:325-335. doi: 10.2147/OPTH.S157430. eCollection 2019. Review.

7.

Novel Use of Deoxycholic Acid for Adiposis Dolorosa (Dercum Disease).

Wipf A, Lofgreen S, Miller DD, Farah RS.

Dermatol Surg. 2019 Feb 14. doi: 10.1097/DSS.0000000000001800. [Epub ahead of print] No abstract available.

PMID:
30789509
8.

Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.

Arnst KE, Banerjee S, Chen H, Deng S, Hwang DJ, Li W, Miller DD.

Med Res Rev. 2019 Jul;39(4):1398-1426. doi: 10.1002/med.21568. Epub 2019 Feb 11. Review.

PMID:
30746734
9.

Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer.

Kashyap VK, Wang Q, Setua S, Nagesh PKB, Chauhan N, Kumari S, Chowdhury P, Miller DD, Yallapu MM, Li W, Jaggi M, Hafeez BB, Chauhan SC.

J Exp Clin Cancer Res. 2019 Jan 23;38(1):29. doi: 10.1186/s13046-018-1009-7.

10.

3,5-Disubstituted-indole-7-carboxamides as IKKβ Inhibitors: Optimization of Oral Activity via the C3 Substituent.

Kerns JK, Busch-Petersen J, Fu W, Boehm JC, Nie H, Muratore M, Bullion A, Lin G, Li H, Davis R, Lin X, Lakdawala AS, Cousins R, Field R, Payne J, Miller DD, Bamborough P, Christopher JA, Baldwin I, Osborn RR, Yonchuk J, Webb E, Rumsey WL.

ACS Med Chem Lett. 2018 Oct 30;9(12):1164-1169. doi: 10.1021/acsmedchemlett.8b00291. eCollection 2018 Dec 13.

PMID:
30613320
11.

New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.

Hwang DJ, He Y, Ponnusamy S, Mohler ML, Thiyagarajan T, McEwan IJ, Narayanan R, Miller DD.

J Med Chem. 2019 Jan 24;62(2):491-511. doi: 10.1021/acs.jmedchem.8b00973. Epub 2018 Dec 26.

PMID:
30525603
12.

How Cognitive Machines Can Augment Medical Imaging.

Miller DD, Brown EW.

AJR Am J Roentgenol. 2019 Jan;212(1):9-14. doi: 10.2214/AJR.18.19914. Epub 2018 Nov 13.

PMID:
30422716
13.

Display of Arms: A Roundtable Discussion about the Public Exhibition of Firearms and Their History.

Tucker J, Adamson G, Ferguson JS, Garrett-Davis J, Goldstein E, Hlebinsky A, Miller DD, Slavick S.

Technol Cult. 2018;59(3):719-769. doi: 10.1353/tech.2018.0064. No abstract available.

PMID:
30245500
14.

Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities.

Wang Q, Arnst KE, Wang Y, Kumar G, Ma D, Chen H, Wu Z, Yang J, White SW, Miller DD, Li W.

J Med Chem. 2018 Sep 13;61(17):7877-7891. doi: 10.1021/acs.jmedchem.8b00827. Epub 2018 Aug 30.

PMID:
30122035
15.

Achieving sustainable and equitable fisheries requires nuanced policies not silver bullets.

Cisneros-Montemayor AM, Cashion T, Miller DD, Tai TC, Talloni-Álvarez N, Weiskel HW, Sumaila UR.

Nat Ecol Evol. 2018 Sep;2(9):1334. doi: 10.1038/s41559-018-0633-0. No abstract available.

PMID:
30038245
16.

The Big Health Data-Intelligent Machine Paradox.

Miller DD.

Am J Med. 2018 Nov;131(11):1272-1275. doi: 10.1016/j.amjmed.2018.05.038. Epub 2018 Jun 25. No abstract available.

PMID:
29953846
17.

Mycobacterium immunogenum folliculitis on the lower extremities of a healthy young adult.

McNeil EP, Goldfarb N, Hannon GR, Miller DD, Farah RS.

Clin Exp Dermatol. 2019 Apr;44(3):328-330. doi: 10.1111/ced.13703. Epub 2018 Jun 19. No abstract available.

PMID:
29920742
18.

Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States.

Micheletti RG, Chiesa-Fuxench Z, Noe MH, Stephen S, Aleshin M, Agarwal A, Boggs J, Cardones AR, Chen JK, Cotliar J, Davis MDP, Dominguez A, Fox LP, Gordon S, Hamrick R, Ho B, Hughey LC, Jones LM, Kaffenberger BH, Kindley K, Kroshinsky D, Kwong BY, Miller DD, Mostaghimi A, Musiek A, Ortega-Loayza AG, Patel R, Posligua A, Rani M, Saluja S, Sharon VR, Shinkai K, John JS, Strickland N, Summers EM, Sun N, Wanat KA, Wetter DA, Worswick S, Yang C, Margolis DJ, Gelfand JM, Rosenbach M.

J Invest Dermatol. 2018 Nov;138(11):2315-2321. doi: 10.1016/j.jid.2018.04.027. Epub 2018 Jul 27. Erratum in: J Invest Dermatol. 2019 Feb;139(2):495-496.

PMID:
29758282
19.

Computationally identified novel agonists for GPRC6A.

Pi M, Kapoor K, Ye R, Hwang DJ, Miller DD, Smith JC, Baudry J, Quarles LD.

PLoS One. 2018 Apr 23;13(4):e0195980. doi: 10.1371/journal.pone.0195980. eCollection 2018.

20.

Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors.

Wang Q, Arnst KE, Xue Y, Lei ZN, Ma D, Chen ZS, Miller DD, Li W.

Eur J Med Chem. 2018 Apr 10;149:211-224. doi: 10.1016/j.ejmech.2018.02.045. Epub 2018 Feb 19.

21.

Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.

Banerjee S, Arnst KE, Wang Y, Kumar G, Deng S, Yang L, Li GB, Yang J, White SW, Li W, Miller DD.

J Med Chem. 2018 Feb 22;61(4):1704-1718. doi: 10.1021/acs.jmedchem.7b01858. Epub 2018 Feb 12.

22.

Investigation of 20S-hydroxyvitamin D3 analogs and their 1α-OH derivatives as potent vitamin D receptor agonists with anti-inflammatory activities.

Lin Z, Marepally SR, Goh ESY, Cheng CYS, Janjetovic Z, Kim TK, Miller DD, Postlethwaite AE, Slominski AT, Tuckey RC, Peluso-Iltis C, Rochel N, Li W.

Sci Rep. 2018 Jan 24;8(1):1478. doi: 10.1038/s41598-018-19183-7.

23.

Destroying the androgen receptor (AR)-potential strategy to treat advanced prostate cancer.

Narayanan R, Ponnusamy S, Miller DD.

Oncoscience. 2017 Dec 28;4(11-12):175-177. doi: 10.18632/oncoscience.389. eCollection 2017 Nov. No abstract available.

24.

Asymptomatic pink plaque on the scapula.

Nguyen CV, Miller DD, Farah RS.

Cutis. 2017 Nov;100(5):E15-E17. No abstract available.

PMID:
29232430
25.

A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.

Arnst KE, Wang Y, Hwang DJ, Xue Y, Costello T, Hamilton D, Chen Q, Yang J, Park F, Dalton JT, Miller DD, Li W.

Cancer Res. 2018 Jan 1;78(1):265-277. doi: 10.1158/0008-5472.CAN-17-0577. Epub 2017 Nov 27.

26.

Artificial Intelligence in Medical Practice: The Question to the Answer?

Miller DD, Brown EW.

Am J Med. 2018 Feb;131(2):129-133. doi: 10.1016/j.amjmed.2017.10.035. Epub 2017 Nov 7. Review.

PMID:
29126825
27.

Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.

Ponnusamy S, Coss CC, Thiyagarajan T, Watts K, Hwang DJ, He Y, Selth LA, McEwan IJ, Duke CB, Pagadala J, Singh G, Wake RW, Ledbetter C, Tilley WD, Moldoveanu T, Dalton JT, Miller DD, Narayanan R.

Cancer Res. 2017 Nov 15;77(22):6282-6298. doi: 10.1158/0008-5472.CAN-17-0976. Epub 2017 Oct 4.

28.

Role of lysophosphatidic acid and its receptors in the kidney.

Park F, Miller DD.

Physiol Genomics. 2017 Nov 1;49(11):659-666. doi: 10.1152/physiolgenomics.00070.2017. Epub 2017 Sep 22. Review.

PMID:
28939644
29.

1α,20S-Dihydroxyvitamin D3 Interacts with Vitamin D Receptor: Crystal Structure and Route of Chemical Synthesis.

Lin Z, Chen H, Belorusova AY, Bollinger JC, Tang EKY, Janjetovic Z, Kim TK, Wu Z, Miller DD, Slominski AT, Postlethwaite AE, Tuckey RC, Rochel N, Li W.

Sci Rep. 2017 Aug 31;7(1):10193. doi: 10.1038/s41598-017-10917-7.

30.

The quinic acid derivative KZ-41 prevents glucose-induced caspase-3 activation in retinal endothelial cells through an IGF-1 receptor dependent mechanism.

He H, Weir RL, Toutounchian JJ, Pagadala J, Steinle JJ, Baudry J, Miller DD, Yates CR.

PLoS One. 2017 Aug 10;12(8):e0180808. doi: 10.1371/journal.pone.0180808. eCollection 2017.

31.

Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.

Chen H, Lin Z, Arnst KE, Miller DD, Li W.

Molecules. 2017 Aug 1;22(8). pii: E1281. doi: 10.3390/molecules22081281. Review.

32.

Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?

Pillai A, Schooler NR, Peter D, Looney SW, Goff DC, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz A, Miller DD, Severe JB, Wilson DR, Ames D, Bustillo J, Kane JM, Buckley PF.

Schizophr Res. 2018 Mar;193:263-268. doi: 10.1016/j.schres.2017.06.059. Epub 2017 Jul 19.

PMID:
28734907
33.

Adaptation strategies to climate change in marine systems.

Miller DD, Ota Y, Sumaila UR, Cisneros-Montemayor AM, Cheung WWL.

Glob Chang Biol. 2018 Jan;24(1):e1-e14. doi: 10.1111/gcb.13829. Epub 2017 Aug 17. Review.

PMID:
28727217
34.

The role of dermatopathology in inpatient care.

Nguyen CV, Miller DD.

Semin Cutan Med Surg. 2017 Mar;36(1):17-22. doi: https://doi.org/10.12788/j.sder.2017.013. Review.

PMID:
28247871
35.

Polymer conjugate of a microtubule destabilizer inhibits lung metastatic melanoma.

Yang R, Mondal G, Ness RA, Arnst K, Mundra V, Miller DD, Li W, Mahato RI.

J Control Release. 2017 Mar 10;249:32-41. doi: 10.1016/j.jconrel.2017.01.028. Epub 2017 Jan 24.

36.

Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells.

Banerjee S, Norman DD, Lee SC, Parrill AL, Pham TC, Baker DL, Tigyi GJ, Miller DD.

J Med Chem. 2017 Feb 23;60(4):1309-1324. doi: 10.1021/acs.jmedchem.6b01270. Epub 2017 Feb 10.

PMID:
28112925
37.

An estrogen receptor β-selective agonist inhibits non-alcoholic steatohepatitis in preclinical models by regulating bile acid and xenobiotic receptors.

Ponnusamy S, Tran QT, Thiyagarajan T, Miller DD, Bridges D, Narayanan R.

Exp Biol Med (Maywood). 2017 Mar;242(6):606-616. doi: 10.1177/1535370216688569. Epub 2017 Jan 16.

38.

How Postpartum Women With Depressive Symptoms Manage Sleep Disruption and Fatigue.

Doering JJ, Sims DA, Miller DD.

Res Nurs Health. 2017 Apr;40(2):132-142. doi: 10.1002/nur.21782. Epub 2017 Jan 13.

PMID:
28084629
39.

Novel Small Molecule JP-153 Targets the Src-FAK-Paxillin Signaling Complex to Inhibit VEGF-Induced Retinal Angiogenesis.

Toutounchian JJ, Pagadala J, Miller DD, Baudry J, Park F, Chaum E, Morales-Tirado V, Yates CR.

Mol Pharmacol. 2017 Jan;91(1):1-13. Epub 2016 Nov 9. Erratum in: Mol Pharmacol. 2017 Dec;92 (6):627.

PMID:
27913654
40.

Follicular Psoriasis: Differentiation from Pityriasis Rubra Pilaris-An Illustrative Case and Review of the Literature.

Nguyen CV, Farah RS, Maguiness SM, Miller DD.

Pediatr Dermatol. 2017 Jan;34(1):e65-e68. doi: 10.1111/pde.13030. Epub 2016 Nov 22. Review.

PMID:
27874201
41.

Serum sickness-like drug reaction: two cases with a neutrophilic urticarial pattern.

Nguyen CV, Miller DD.

J Cutan Pathol. 2017 Feb;44(2):177-182. doi: 10.1111/cup.12863. Epub 2016 Dec 15.

PMID:
27862184
42.

Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis.

Banerjee S, Hwang DJ, Li W, Miller DD.

Molecules. 2016 Nov 2;21(11). pii: E1468. Review.

43.

Epidemiology of Bednar tumors in the United States.

Liszewski W, Blanchette D, Cunningham AM, Miller DD.

J Am Acad Dermatol. 2016 Nov;75(5):1064-1066. doi: 10.1016/j.jaad.2016.06.018. No abstract available.

PMID:
27745635
44.

Pharmacologic activation of estrogen receptor β increases mitochondrial function, energy expenditure, and brown adipose tissue.

Ponnusamy S, Tran QT, Harvey I, Smallwood HS, Thiyagarajan T, Banerjee S, Johnson DL, Dalton JT, Sullivan RD, Miller DD, Bridges D, Narayanan R.

FASEB J. 2017 Jan;31(1):266-281. doi: 10.1096/fj.201600787RR. Epub 2016 Oct 12.

45.

Histopathology of vascular anomalies: update based on the revised 2014 ISSVA classification.

Miller DD, Gupta A.

Semin Cutan Med Surg. 2016 Sep;35(3):137-46. doi: 10.12788/j.sder.2016.053. Review.

PMID:
27607322
46.

Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study.

Buckley PF, Schooler NR, Goff DC, Kopelowicz A, Lauriello J, Manschreck TC, Mendelowitz A, Miller DD, Wilson DR, Ames D, Bustillo JR, Kane JM, Looney SW.

Psychiatr Serv. 2016 Dec 1;67(12):1370-1372. Epub 2016 Aug 1.

PMID:
27476806
47.

Changing nodule on the right helix.

Nguyen CV, Miller DD, Hylwa SA.

Int J Dermatol. 2017 May;56(5):483-485. doi: 10.1111/ijd.13354. Epub 2016 Jun 23. Review. No abstract available.

PMID:
27337342
48.

Synthesis and Biological Evaluation of Vitamin D3 Metabolite 20S,23S-Dihydroxyvitamin D3 and Its 23R Epimer.

Lin Z, Marepally SR, Ma D, Kim TK, Oak AS, Myers LK, Tuckey RC, Slominski AT, Miller DD, Li W.

J Med Chem. 2016 May 26;59(10):5102-8. doi: 10.1021/acs.jmedchem.6b00182. Epub 2016 Apr 22.

49.

Design, Synthesis and Biological Activities of Novel Gemini 20S-Hydroxyvitamin D3 Analogs.

Lin Z, Marepally SR, Kim TK, Janjetovic Z, Oak AS, Postlethwaite AE, Myers LK, Tuckey RC, Slominski AT, Miller DD, Li W.

Anticancer Res. 2016 Mar;36(3):877-86.

50.

Heterochromatin Protein 1 Binding Protein 3 Expression as a Candidate Marker of Intrinsic 5-Fluorouracil Resistance.

Hadac JN, Miller DD, Grimes IC, Clipson L, Newton MA, Schelman WR, Halberg RB.

Anticancer Res. 2016 Mar;36(3):845-52.

Supplemental Content

Loading ...
Support Center